Njira Lugogo, MD
Pulmonary Disease · Ann Arbor, MINPI 1649219734
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $567,650 of the $740,912 with a category attached, or 76.6%. 19 manufacturers reported payments, led by GSK at 38.8% of the total. Among pulmonary disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 535 payments — averaging $1384.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$288K
- AstraZeneca$156K
- Astrazeneca UK Limited$76K
- Teva Pharmaceuticals USA, Inc.$63K
- Sanofi$58K
- Regeneron$35K
- plus $65K from 13 others
Across 1,485 payments — averaging $8246.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$5.7M
- Teva Pharmaceuticals USA, Inc.$2.3M
- Janssen Research & Development, LLC$1.9M
- Genentech, Inc.$482K
- GSK$452K
- Regeneron$452K
- plus $975K from 7 others
What the payments were for
- Consulting fees$567,65077%
- Speaking & faculty fees$81,32411%
- Travel & lodging$80,51111%
- Food & beverage$11,4182%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 186 | $287,549 |
| AstraZeneca | 150 | $156,397 |
| Astrazeneca UK Limited | 48 | $75,911 |
| Teva Pharmaceuticals USA, Inc. | 26 | $62,801 |
| Sanofi | 24 | $58,295 |
| Regeneron | 21 | $34,605 |
| Regeneron Healthcare Solutions, Inc. | 24 | $14,540 |
| Genentech USA, Inc. | 15 | $10,661 |
| Astrazeneca AB | 11 | $9,136 |
| Chiesi USA, Inc. | 7 | $9,128 |
| Sanofi-aventis U.S. LLC | 2 | $8,695 |
| Amgen | 11 | $5,593 |
| Pfizer | 2 | $3,125 |
| Incyte Corporation | 2 | $2,445 |
| Novartis | 1 | $1,330 |
| AbbVie | 1 | $575 |
| Insmed, Inc. | 1 | $44 |
| Genentech, Inc. | 2 | $41 |
| Circassia Inc. | 1 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$87,284
- DUPIXENT$83,314
- FASENRA$62,751
- TEZSPIRE$36,206
- TRELEGY ELLIPTA$22,010
- ProAir Digihaler$14,845
- AirDuo Digihaler$13,563
- AIRSUPRA$12,160
- XOLAIR$10,405
- BREZTRI$6,948
- ArmonAir Digihaler$1,845
- SAPHNELO$537
How this compares
$740,912 in reported general payments places this provider in the 95th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 168 | $736,276 |
| Fasenra PenBenralizumab | 86 | $463,736 |
| Dupixent PenDupilumab | 110 | $421,291 |
| Dupixent SyringeDupilumab | 110 | $416,647 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 203 | $157,384 |
| NucalaMepolizumab | 27 | $114,627 |
| Spiriva RespimatTiotropium Bromide | 135 | $97,369 |
| XolairOmalizumab | 22 | $63,947 |
| Advair HfaFluticasone Propion/Salmeterol | 56 | $29,694 |
| SymbicortBudesonide/Formoterol Fumarate | 60 | $27,210 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $21,530 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $21,389 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 55 | $20,159 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 87 | $16,179 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $9,338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere | $156,397 | $784,875254 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta | $287,549 | $300,428278 claims |
| Genentech, Inc.Xolair | $41 | $63,94722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Ann Arbor
- Meilan HanAnn Arbor$779K
- Justin OldhamAnn Arbor$392K
- Kevin FlahertyAnn Arbor$328K
- Jose de CardenasAnn Arbor$115K
- Timothy BlackwellAnn Arbor$99K
- Philip ChoiAnn Arbor$54K
- Jeanette BrownAnn Arbor$38K
- Jeffrey CurtisAnn Arbor$37K
- Vibha LamaAnn Arbor$26K
- Eric WhiteAnn Arbor$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.